This week is a major deadline for NIH grant applications. But across academic medicine, senior researchers are warning their junior colleagues about the endeavor - the funding is too unstable to count on.
And they’re not wrong. Our own colleagues have been on the receiving end of this instability. Over the winter, one secured their first R01 grant, a prestigious NIH award for innovative biomedical research. The project represented years of preparation and promised to advance both clinical practice and scientific understanding. It was exactly the kind of work that academic medicine is designed to foster.
Then came the call earlier this year: their funding was frozen.
Not because of any problems with the science, but because a collaborating institution had been caught up in the Trump administration’s broader funding holds. Despite having no direct connection to the political issues that triggered the freeze, the entire collaborative project was now in limbo.
“I can’t build a career on something that can be dismantled overnight by people who don’t understand science,” my colleague explained when describing their decision to pivot away from basic research toward more commercially oriented work. “At least in industry, the uncertainty is market-based, not political.”
This threatens to undermine one of America’s most successful economic investments. The true cost of what’s happening isn’t just the loss of individual research grants: it’s the collapse of a system that has delivered extraordinary returns to American taxpayers and established the United States as the world’s scientific superpower.
The Efficiency Argument
It’s important to recognize the context this has all happened within. Even my own father argues that there is “too much waste in government sponsored research.” But here’s what critics calling for “efficiency” miss: NIH-funded research is one of the federal government’s most efficient investments. Every dollar spent generates $2.46 in economic activity, and basic research stimulates $8.38 in additional private R&D investment. The Human Genome Project alone now generates more than 166,000 direct U.S. jobs and 850,000 indirect jobs. Recent research from MIT found that more than half of FDA-approved drugs since 2000 trace back to NIH grants that would have been eliminated under proposed 40% budget cuts. As MIT economist Danielle Li noted, “The worry is that these kinds of deep cuts to the NIH risk that foundation and therefore endanger the development of medicines that might be used to treat us, or our kids and grandkids, 20 years from now.”
This isn’t wasteful spending: it’s the engine of American biomedical innovation that generates trillions in economic value and supports over seven million jobs. Thankfully, at least before the RFK Jr. led HHS, the American public seemed to understands this. Three-quarters (74%) of voters support federal investment in scientific research, with strong bipartisan backing.
But this efficiency depends entirely on career stability. You can’t get 20-year drug development timelines from researchers who can’t plan past the next funding freeze.
A Fragile Ecosystem
To understand why uncertainty is so toxic to scientific progress, you have to grasp just how precarious the academic research career path already is. Ten years after graduation, only about one third of biomedical PhD recipients were in academic research positions. The other two-thirds had already left for industry, government, or other careers.
This isn’t necessarily a failure. Academic researchers accept lower salaries and intense competition because the trade-off has traditionally been autonomy to pursue important questions without immediate commercial pressure. The delayed gratification comes from the intellectual freedom and the possibility of making discoveries that matter.
For medical researchers like me, consider the financial sacrifice involved. Medical school students graduate with an average of $215,900 in debt (I’m average!). After medical school, students typically pursue postdoctoral positions, which last two to three years, although it’s common to complete more than one postdoc in the U.S. As of 2024, the average salary for postdocs was $61,000 to $72,000 per year. MD-PhD graduates face an even longer path to establishing independent research careers: the median time to first academic faculty position (instructor or assistant professor) after graduation was six years, according to the National MD-PhD Program Outcomes Study.
Generally, it is understood that these researchers aren’t motivated primarily by money. They’re willing to accept years of financial hardship for the opportunity to tackle humanity’s biggest challenges with stable, long-term support. But this system only works if that support is actually stable and long-term.
Uncertainty Can Become a Tax
The rapid destabilization brought on by the Department of government efficiency (DOGE) in 2025 have revealed how quickly this delicate ecosystem can be disrupted. In January, the new administration barred the NIH from posting any new notices to the Federal Register as part of a freeze on communications across health agencies. The immediate impact was the cancellation of dozens of study sections—the expert panels that determine which research projects deserve funding.
While some study sections eventually resumed, the damage was deeper than any budget cut. The National Cancer Institute, for example, informed scientists in late July that it expected to be able to fund just 4% of grant applications, down from 9%. This new administration policy affects multiple branches of NIH and will ratchet up competition for grants to an unprecedented level.
Some might say, “But the funding came back, so what’s the problem?” This misses the point. Even if/when funding levels are restored—as they have been in some cases—the psychological damage persists. The uncertainty creates a “tax” on scientific careers: an additional cost that has nothing to do with the work itself but everything to do with the political environment surrounding it.
The tumult, in and of itself, matters. A researcher planning their career in 2025 now knows that despite years of planning and coordinating and approvals, their funding can be frozen without warning, that study sections can be cancelled mid-review, and that political considerations can override scientific merit at any moment. This knowledge doesn’t disappear when the money is restored. It changes the risk calculus of choosing academic research over more stable career paths.
This uncertainty tax operates through several mechanisms:
Career Planning Becomes Impossible: Scientific training requires decades-long commitments. A researcher might spend four years in graduate school, three to five years as a postdoc (funded by training grants), and then several more years establishing an independent lab (funded by career development awards). When that funding can be frozen or eliminated based on political whims rather than scientific merit, rational people choose more predictable career paths.
Risk Tolerance Shifts: The most entrepreneurial and adaptable researchers - exactly the ones who might generate breakthrough discoveries - are also the most likely to have attractive opportunities outside academia. When research careers become politically unstable, these individuals, as personal friends have done, found startups instead of establishing academic labs, changing the dynamics and expectations for returns on investment.
Institutional Memory Erodes: Every researcher who leaves academic science takes with them not just their individual expertise, but their role in training the next generation. The number of biomedical PhD scientists undergoing training and graduating far exceeds the number of academic faculty positions and academic research jobs, meaning the system was already struggling to retain talent before adding political uncertainty to the mix.
When Expertise Becomes Suspect
The uncertainty isn’t just about whether you’ll be funded—it’s about whether the work itself is valued. With the appointment of Robert F. Kennedy Jr. as Health and Human Services Secretary and his systematic dismantling of scientific advisory committees, early-career researchers face a more fundamental question: Does this career path even have long-term value?
Research shows that politicization of public services leads to worse outcomes as public employees invest less in developing their expertise and become more likely to exit. When Kennedy fired all 17 members of the Advisory Committee on Immunization Practices in early June, claiming without evidence the need to remove “conflicts of interest,” he sent a clear message: specialized expertise isn’t just undervalued—it’s suspect.
The toll on early-career researchers has been severe, with scientists warning that “these kinds of shocks are going to lead to a mass exodus” and predicting “a missing age class of researchers that will reverberate for years.” Why spend a decade acquiring specialized knowledge if political appointees with no relevant training can dismiss that expertise as a conflict of interest? This pushes talented people away from science entirely, choosing careers where their expertise will be respected rather than questioned.
The Network Effects of Talent Loss
Academic research doesn’t advance through lone geniuses—it depends on networks of collaboration and mentorship built over decades. A senior researcher trains postdocs who establish their own labs and train the next generation, creating chains of expertise spanning institutions. Multi-institution projects rely on years of established relationships. These networks are fragile, built on trust and continuity.
Political uncertainty is fracturing them. When my colleague’s R01 grant was frozen mid-project, it disrupted a multi-institution collaboration years in the making. Senior scientists at the NIH, FDA, and CDC are considering early retirement, accelerating the loss of institutional knowledge. Each departure breaks mentorship chains and severs collaborative relationships built over decades.
The consequences compound. When early-career researchers leave for industry, they take not just their talent but their future role in training the next generation. The postdoc who might have run a lab and trained dozens of researchers over 30 years joins a startup focused on five-year product cycles instead. The networks that would have formed around their work never materialize.
Consider what’s at stake. Checkpoint inhibitor cancer immunotherapy—breakthrough treatments extending survival for thousands and generating billions in economic value—emerged from decades of collaborative basic research at Harvard, Stanford, and the NIH. The NIH Proof of Concept Network has supported over 3,000 academic innovators, creating more than 100 startup companies and attracting $1.58 billion in additional funding. This is what thrives under stable conditions.
But the system depends on trust: that funding will be there, that expertise will be respected, that long-term thinking will be valued over short-term political wins. When that trust erodes, the networks fracture—and the breakthroughs that might have emerged never happen.
We Can Fix This
The damage is real, but it’s reversible. The solution isn’t complex - it requires recognizing that scientific careers operate on different timescales than political cycles. Research programs that might revolutionize medicine or create entire industries need consistent support over decades, not the political equivalent of quarterly earnings reports.
We also need institutional firewalls: mechanisms that insulate scientific funding decisions from political interference while maintaining democratic oversight. The NIH’s peer review system was designed to do exactly this: ensure that funding decisions follow scientific merit, not political considerations. But peer review only works if its results are honored, not overridden by whoever holds power.
Finally, the economic case is overwhelming. The public supports stable research funding across party lines. The only question is whether our political system can resist treating scientific research as just another partisan issue to reorganize with each administration. I’m not sure it can.
The Stakes of Inaction
Every month of funding uncertainty is another month when some of the most brilliant young researchers choose industry over academia, when collaborative networks fragment, when America’s scientific leadership erodes. These losses compound in ways that can’t be easily reversed.
My colleague’s pivot to entrepreneurship might seem like a happy ending. Hey, they’re still doing important work! But their startup will focus on products that can be commercialized quickly, not the fundamental research questions that might lead to entirely new approaches to care. That’s the tragedy of the uncertainty tax: it doesn’t just reduce the number of researchers, it systematically biases the system toward short-term thinking.
The United States became the world’s scientific superpower by betting that long-term investment in basic research would pay extraordinary dividends. The numbers prove that bet was right. We’ve generated trillions in economic value and saved millions of lives through federally funded research.
So do we continue that successful model by providing the career stability that attracts the world’s brightest minds, or watch our scientific leadership erode as political uncertainty drives talent away from the very system that made America an innovation powerhouse?
The uncertainty tax is already being collected. The question is whether we’ll realize the cost before it’s too late to reverse the damage.